Administration of neutralizing anti-IFNα/β antibodies to resistant B6D2/F1 mice prior to and upon infection with M. tuberculosis HN878 provided a long-term survival benefit, associated with lower IFN-α expression and STAT1 activation in lung tissue, albeit without significant effects on bacterial burden (90). This evidence concerns the gene IFNA2 and infection.